Lilly's Pancreatic Cancer Candidate Fails In Phase III Study
Zacks Investment Research | Oct 16, 2019 11:24PM ET
Eli Lilly and Company (NYSE:LLY) announced that its immunotherapy candidate, pegilodecakin, in combination with chemotherapies, failed to show survival benefit in a phase III SEQUOIA study, evaluating the regimen in metastatic pancreatic cancer.
Shares of the company fell 1.6% on Oct 16 following announcement of the study failure. The company’s shares decreased 6.7% against the industry ’s increase of 0.2%.
The SEQUOIA study evaluated pegilodecakin in combination with FOLFOX, which is a combination of chemotherapies (folinic acid, 5-FU, oxaliplatin), in patients with metastatic pancreatic cancer whose disease had progressed during or following a first-line gemcitabine-containing regimen versus FOLFOX alone for improvement in overall survival. The study failed to meet the primary endpoint of overall survival.
Please note that Lilly added pegilodecakin to its pipeline with the acquisition of ARMO Biosciences in 2018.
Apart from pancreatic cancer, Lilly is also evaluating pegilodecakin in combination with checkpoint inhibitors in two phase II studies as a treatment for non-small cell lung cancer. Top-line data from these studies are expected in early 2020. The company also has plans to develop the candidate for treating other tumor types including renal cell carcinoma.
Currently, pancreatic cancer is the third most common type of cancer leading to death in U.S. patients per the American Cancer Society. Per the press release, more than 56,700 patients will be diagnosed with pancreatic cancer in 2019.
Although Lilly markets Gemzar for pancreatic cancer, the drug, once a blockbuster, does not generate significant sales due to generic competition. Other drugs available for pancreatic cancer include Celgene’s (NASDAQ:CELG) Abraxane and Roche’s Tarceva.
Several other pharma/biotech companies are developing their treatment regimens to cater to this significantly growing market. NuCana plc (NASDAQ:NCNA) is evaluating Acelarin in phase III study, Clovis Oncology’s Rubraca is in mid-stage development and Tyme Technologies, Inc. (NASDAQ:TYME) initiated a pivotal study on its pipeline candidate racemetyrosine last month.
We note that Lilly’s oncology segment remained the second largest revenue generator for the company in the first half of 2019 with $2.2 billion in sales. Key oncology drugs of the company are Alimta, Cyramza and Erbitux, which are approved for multiple cancer indications. Successful development of pegilodecakin for treating pancreatic cancer would have offset lower sales of Gemzar as well as boosted oncology sales.
Get The News You Want
Eli Lilly and Company Price
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.